NCT01896609 - Trial Comparing the Efficacy, Tolerability and Safety Between Three Arms in Treatment of HCV in Egyptian Population | Biotech Hunter

Enrollment

300

Participants

Timeline

Start Date

June 30, 2013

Primary Completion Date

January 31, 2015

Study Completion Date

June 30, 2015

Conditions

Chronic Hepatitis c

Interventions

BIOLOGICAL

Reiferon Retard in Arm 1

Arm 1,2,3 Reiferon Retard® 160 µg /week subcutaneous injection for 48 weeks

DRUG

Bon one in Arm 3

Arm 3 , Bon One ® 0.5 µg daily orally for 48 weeks

DRUG

Xerovirinc in Arm 2

Arm 2,3 Xerovirinc® 500mg twice daily orally for 48 weeks

DRUG

Ribavirin in Arm 1

Arm 1,2,3 Ribavirin in a dose of 13 mg/kg/day orally for 48 weeks

Trial Locations (1)

RECRUITING

Faculty of Medicine , Cairo University, Cairo